Understanding new discovery and engineering technologies and approaches being used by other drug developers is critical. Learning how to take them forward within your organization is priceless.
That’s where this conference comes in.
Unlike other antibody conferences, Antibody Engineering and Discovery 2013 was a meeting that didn’t just give you a comprehensive overview and in-depth understanding and of what other drug developers are doing…
It was also a meeting that noticeably changed the way you operated on your return to the lab, by giving you the opportunity to uncover how to use the new approaches used by your competitors. All so that you can move your own antibody pipeline forward.
With a focus on delivering results in a commercial environment, this meeting that helped you:
Because delivering in a commercial environment was the focus, speakers and delegates were dominated by drug developers who could tell you first-hand how to discover and develop differentiated antibodies. Presenters included heads of antibody programs from Pfizer, Novartis, Merck, AbbVie, MedImmune, Amgen and BMS.
Heavyweights of the antibody field, George Georgiou and Ira Pastan, outlined radically different discovery and engineering approaches that helped propel your development efforts forwards. Plus, the FDA updated you on their evolving regulatory expectations regarding antibody development.
This was a very different type of antibody meeting. You’ve previously said that the quality of discussion and the usability of the knowledge you take away from the meeting is critical.
The conference delivered information that’ll make a tangible difference to your performance. A premium is placed on knowledge sharing and networking. Here’s how:
"High quality speakers, high content presentations and lots of opportunities for networking" Pfizer
“Nice agenda, top notch speakers, and great presentations and speed networking.” Aldevron
“The most profitable event we’ve ever attended.” Immunologix
“A good venue for review of the antibody engineering industry and opportunity to learn some new breakthroughs.” Abbott